MX2021001186A - Purinonas como inhibidores de proteasa especifica de ubiquitina 1. - Google Patents
Purinonas como inhibidores de proteasa especifica de ubiquitina 1.Info
- Publication number
- MX2021001186A MX2021001186A MX2021001186A MX2021001186A MX2021001186A MX 2021001186 A MX2021001186 A MX 2021001186A MX 2021001186 A MX2021001186 A MX 2021001186A MX 2021001186 A MX2021001186 A MX 2021001186A MX 2021001186 A MX2021001186 A MX 2021001186A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- inhibitors
- purinones
- ubiquitin
- specific protease
- Prior art date
Links
- 101000607909 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 1 Proteins 0.000 title abstract 3
- 102100039865 Ubiquitin carboxyl-terminal hydrolase 1 Human genes 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- UFZNZKGKBWOSJG-UHFFFAOYSA-N purin-2-one Chemical class O=C1N=CC2=NC=NC2=N1 UFZNZKGKBWOSJG-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
La solicitud se refiere a inhibidores de USP1 útiles en el tratamiento de cánceres, y otras enfermedades y trastornos asociados con USP1. con la Fórmula: (ver Fórmula) donde R1, R2, R3, R3', R4, R5, X1, X2, X3, X4, y n se describen en la presente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562258162P | 2015-11-20 | 2015-11-20 | |
PCT/US2016/062837 WO2017087837A1 (en) | 2015-11-20 | 2016-11-18 | Purinones as ubiquitin-specific protease 1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021001186A true MX2021001186A (es) | 2022-10-11 |
Family
ID=57472109
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018005925A MX2018005925A (es) | 2015-11-20 | 2016-11-18 | Purinonas como inhibidores de proteasa específica de ubiquitina 1. |
MX2021001186A MX2021001186A (es) | 2015-11-20 | 2016-11-18 | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018005925A MX2018005925A (es) | 2015-11-20 | 2016-11-18 | Purinonas como inhibidores de proteasa específica de ubiquitina 1. |
Country Status (13)
Country | Link |
---|---|
US (4) | US10189841B2 (es) |
EP (2) | EP3696181A1 (es) |
JP (3) | JP6964343B2 (es) |
KR (1) | KR20180095539A (es) |
CN (2) | CN108473495B (es) |
AU (3) | AU2016356694B2 (es) |
BR (1) | BR112018010216B1 (es) |
CA (1) | CA3005353A1 (es) |
IL (3) | IL300788A (es) |
MX (2) | MX2018005925A (es) |
RU (1) | RU2750151C2 (es) |
SG (1) | SG11201804098TA (es) |
WO (1) | WO2017087837A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018010216B1 (pt) | 2015-11-20 | 2024-02-15 | Forma Therapeutics, Inc | Purinonas como inibidores da protease específica da ubiquitina 1 e composição farmacêutica compreendendo os referidos compostos |
EP3703669A4 (en) | 2017-11-01 | 2021-11-10 | Dana-Farber Cancer Institute, Inc. | CANCER TREATMENT METHODS |
WO2019189731A1 (ja) | 2018-03-30 | 2019-10-03 | 住友化学株式会社 | 複素環化合物及びそれを含有する有害節足動物防除組成物 |
KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
CA3108676A1 (en) * | 2018-08-09 | 2020-02-13 | David J. Guerin | Carboxamides as ubiquitin-specific protease inhibitors |
CN109503421B (zh) * | 2018-11-20 | 2022-10-14 | 黎明化工研究设计院有限责任公司 | 一种提高叠氮胺燃料合成过程安全性的方法 |
BR112021010715A2 (pt) * | 2018-12-20 | 2021-11-16 | Ksq Therapeutics Inc | Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1) |
WO2020139988A1 (en) * | 2018-12-28 | 2020-07-02 | Forma Therapeutics, Inc. | Compositions for inhibiting ubiquitin specific protease 1 |
WO2020240493A1 (en) * | 2019-05-31 | 2020-12-03 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
US20230092890A1 (en) * | 2019-05-31 | 2023-03-23 | Chong Kun Dang Pharmaceutical Corp. | 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
CN110759902B (zh) * | 2019-11-01 | 2022-04-22 | 海南一龄医疗产业发展有限公司 | Set8赖氨酸甲基转移酶抑制剂及其制备方法和用途 |
KR102458689B1 (ko) * | 2020-07-08 | 2022-10-25 | 원광대학교산학협력단 | 피페리딘 화합물 및 이의 제조 방법 |
KR20220030134A (ko) * | 2020-09-02 | 2022-03-10 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 새로운 구조의 화합물 및 이를 포함하는 약제학적 조성물 |
CN111926018B (zh) * | 2020-09-04 | 2022-07-12 | 首都医科大学附属北京儿童医院 | 降低usp1表达的物质在制备治疗儿童t系急性淋巴细胞白血病的药物中的应用 |
JP2023548148A (ja) | 2020-10-30 | 2023-11-15 | ケーエスキュー セラピューティクス, インコーポレイテッド | 置換ピラゾロピリミジンの固体形態及びその使用 |
CN117425656A (zh) * | 2021-03-17 | 2024-01-19 | 探戈医药股份有限公司 | 作为抗癌剂的嘌呤衍生物 |
CN116917288A (zh) * | 2021-03-22 | 2023-10-20 | 成都赜灵生物医药科技有限公司 | 一种7,9-二氢嘌呤衍生物及其制药用途 |
IL307157A (en) * | 2021-04-07 | 2023-11-01 | Forma Therapeutics Inc | Ubiquitin-specific protease 1 (USP1) inhibition |
WO2023069959A1 (en) * | 2021-10-18 | 2023-04-27 | Dana-Farber Cancer Institute, Inc. | Covalent egfr inhibitors and methods of use thereof |
WO2023086521A1 (en) * | 2021-11-10 | 2023-05-19 | Biogen Ma Inc. | Btk inhibitors |
CA3235603A1 (en) * | 2021-11-12 | 2023-05-19 | Insilico Medicine Ip Limited | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
WO2023083286A1 (en) * | 2021-11-12 | 2023-05-19 | Insilico Medicine Ip Limited | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
WO2023148643A1 (en) * | 2022-02-03 | 2023-08-10 | Aurigene Oncology Limited | Fused bicyclic heterocyclyl compounds as usp1 inhibitors |
CN116496252A (zh) * | 2022-04-29 | 2023-07-28 | 江苏亚虹医药科技股份有限公司 | 嘧啶类化合物、其制备方法及其医药用途 |
WO2023250084A1 (en) * | 2022-06-23 | 2023-12-28 | Forma Therapeutics, Inc. | Usp1 inhibitors and uses thereof |
US20240092779A1 (en) * | 2022-06-29 | 2024-03-21 | Zentaur Therapeutics Usa Inc. | Usp1 inhibitors and uses thereof |
WO2024022266A1 (en) * | 2022-07-25 | 2024-02-01 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heteroaryl compounds as inhibitors of usp1 |
WO2024022519A1 (zh) * | 2022-07-28 | 2024-02-01 | 先声再明医药有限公司 | 杂环并嘧啶类化合物及其应用 |
WO2024041634A1 (zh) * | 2022-08-26 | 2024-02-29 | 先声再明医药有限公司 | 三环类化合物及其应用 |
WO2024051795A1 (zh) * | 2022-09-09 | 2024-03-14 | 正大天晴药业集团股份有限公司 | 用作泛素-特异性蛋白酶抑制剂的取代嘌呤酮衍生物 |
WO2024061213A1 (zh) * | 2022-09-20 | 2024-03-28 | 正大天晴药业集团股份有限公司 | 用作泛素-特异性蛋白酶抑制剂的羰基稠合杂环衍生物 |
WO2024078436A1 (zh) * | 2022-10-09 | 2024-04-18 | 海南先声再明医药股份有限公司 | 杂环并嘧啶类化合物、药物组合物及其应用 |
WO2024086790A1 (en) | 2022-10-21 | 2024-04-25 | Exelixis, Inc. | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS |
CN116621846B (zh) * | 2023-07-24 | 2023-10-17 | 华润医药研究院(深圳)有限公司 | 双环杂环及三环杂环类化合物及其制备方法和医药用途 |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4859672A (en) | 1986-10-29 | 1989-08-22 | Rorer Pharmaceutical Corporation | Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone |
JPS63199347A (ja) | 1987-02-14 | 1988-08-17 | Konica Corp | 鮮鋭性の向上した高感度ハロゲン化銀写真感光材料 |
FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
US6444656B1 (en) | 1992-12-23 | 2002-09-03 | Biochem Pharma, Inc. | Antiviral phosphonate nucleotides |
GB9226879D0 (en) | 1992-12-23 | 1993-02-17 | Iaf Biochem Int | Anti-viral compounds |
ES2222614T3 (es) | 1997-11-12 | 2005-02-01 | Mitsubishi Chemical Corporation | Derivados de purina y medicina que los contiene como ingrediente activo. |
ZA9810490B (en) | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
TW572758B (en) * | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
JP3814125B2 (ja) | 1999-06-02 | 2006-08-23 | 大日本住友製薬株式会社 | 2−アリール−8−オキソジヒドロプリン誘導体からなる医薬 |
AU3540101A (en) | 2000-01-07 | 2001-07-16 | Universitaire Instelling Antwerpen | Purine derivatives, process for their preparation and use thereof |
JP3675274B2 (ja) | 2000-01-27 | 2005-07-27 | ダイソー株式会社 | 9−(2−ヒドロキシアルキル)プリン誘導体および1−(2−ヒドロキシアルキル)ピリミジン誘導体の製造法 |
US6630478B2 (en) | 2000-07-07 | 2003-10-07 | Neotherapeutics, Inc. | Methods for treatment of drug-induced peripheral neuropathy |
US20020040031A1 (en) | 2000-07-07 | 2002-04-04 | Glasky Michelle S. | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system |
US20020040032A1 (en) | 2000-07-07 | 2002-04-04 | Glasky Michelle S. | Methods for stimulation of synthesis of synaptophysin in the central nervous system |
US20020128264A1 (en) | 2000-07-07 | 2002-09-12 | Taylor Eve M. | Methods for treatment of conditions affected by activity of multidrug transporters |
WO2002058736A2 (en) | 2000-12-12 | 2002-08-01 | Neotherapetics, Inc. | Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis |
US20020156277A1 (en) | 2001-04-20 | 2002-10-24 | Fick David B. | Synthesis and methods of use of purine analogues and derivatives |
US7285658B2 (en) | 2002-02-28 | 2007-10-23 | Biota, Inc. | Nucleotide mimics and their prodrugs |
US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
US7371857B2 (en) | 2002-08-08 | 2008-05-13 | Valeant Research & Development | Synthesis for hydroxyalkylated heterocyclic bases |
US20040166137A1 (en) | 2002-11-08 | 2004-08-26 | Lackey John William | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
JP2004217582A (ja) | 2003-01-16 | 2004-08-05 | Abbott Japan Co Ltd | 9h−プリン誘導体 |
WO2005010003A1 (en) | 2003-07-23 | 2005-02-03 | Wyeth | Sulfonyldihydroimid- azopyridinone compounds as 5-hydroxytryptamine-6 ligands |
US20050043239A1 (en) | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
US20050239809A1 (en) | 2004-01-08 | 2005-10-27 | Watts Stephanie W | Methods for treating and preventing hypertension and hypertension-related disorders |
EP1750714A1 (en) | 2004-05-13 | 2007-02-14 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
EP1755609A1 (en) | 2004-05-25 | 2007-02-28 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
EP1750715A1 (en) | 2004-06-04 | 2007-02-14 | Icos Corporation | Methods for treating mast cell disorders |
CA2596424C (en) | 2005-02-04 | 2016-03-29 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzymes |
WO2006089106A2 (en) | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
MX2007012393A (es) | 2005-04-05 | 2008-02-22 | Pharmacopeia Inc | Derivados de purina e imidazopiridina para la inmunosupresion. |
US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
US20090023723A1 (en) | 2005-09-21 | 2009-01-22 | Pharmacopeia Drug Discovery, Inc. | Purinone derivatives for treating neurodegenerative diseases |
US7989459B2 (en) | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
US7754463B2 (en) | 2006-06-20 | 2010-07-13 | Dana-Farber Cancer Institute | Inhibitors of USP1 Deubiquitinating Enzyme Complex |
EP2471529A3 (en) * | 2006-09-05 | 2012-10-10 | Emory University | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof |
WO2008030744A2 (en) * | 2006-09-05 | 2008-03-13 | Board Of Regents, The University Of Texas System | Inhibitors of c-met and uses thereof |
WO2008045529A1 (en) | 2006-10-12 | 2008-04-17 | Serenex, Inc. | Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases |
NZ576279A (en) * | 2006-10-19 | 2011-12-22 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
CA2669686A1 (en) | 2006-11-16 | 2008-05-22 | Pharmacopeia, Llc | 7-substituted purine derivatives for immunosuppression |
US20080119496A1 (en) | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
WO2008118454A2 (en) | 2007-03-23 | 2008-10-02 | Amgen Inc. | Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer |
WO2008117796A1 (ja) | 2007-03-28 | 2008-10-02 | Dainippon Sumitomo Pharma Co., Ltd. | 新規ムチリン誘導体 |
US20090182035A1 (en) | 2007-04-11 | 2009-07-16 | Alcon Research, Ltd. | Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis |
RU2009141592A (ru) | 2007-04-11 | 2011-05-20 | Алькон Рисерч, Лтд. (Us) | ПРИМЕНЕНИЕ ИНГИБИТОРА TNFα В СОЧЕТАНИИ С АНТИГИСТАМИННЫМ СРЕДСТВОМ ДЛЯ ЛЕЧЕНИЯ АЛЛЕРГИЧЕСКОГО РИНИТА И АЛЛЕРГИЧЕСКОГО КОНЪЮНКТИВИТА |
WO2008131501A2 (en) | 2007-04-27 | 2008-11-06 | Katholieke Universiteit Leuven | New anti-viral nucleoside analogs |
GB0708258D0 (en) | 2007-04-27 | 2007-06-06 | Katholleke Universiteit Leuven | New anti-viral nulceoside analogs |
WO2008143674A1 (en) | 2007-05-23 | 2008-11-27 | Pharmacopeia, Inc. | Purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
KR20100023907A (ko) | 2007-06-26 | 2010-03-04 | 사노피-아벤티스 | 벤즈이미다졸 및 아자벤즈이미다졸의 위치선택적 구리 촉매화 합성 |
JP2009007273A (ja) | 2007-06-27 | 2009-01-15 | Ajinomoto Co Inc | ジアミノピリミジン化合物の製造方法 |
US20090118301A1 (en) | 2007-11-02 | 2009-05-07 | Arbor Vita Corporation | Compositions and Methods for Treating Cancer |
WO2009062059A2 (en) | 2007-11-08 | 2009-05-14 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
US8404856B2 (en) | 2007-11-20 | 2013-03-26 | Merck Sharp & Dohme Corp. | Non-nucleoside reverse transcriptase inhibitors |
CA2722308C (en) | 2008-04-15 | 2024-02-27 | Rfs Pharma, Llc. | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
US9062056B2 (en) | 2008-09-09 | 2015-06-23 | Boehringer Ingelheim International Gmbh | Aza-benzimidazolone Chymase inhibitors |
JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン, エルエルシー | 複素環キナーゼ阻害剤 |
CA2778680C (en) | 2009-10-29 | 2016-12-13 | Carmen Almansa Rosales | N-containing heteroaryl derivatives as jak3 kinase inhibitors |
JP2011136925A (ja) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | 含窒素二環性化合物 |
US9555033B2 (en) | 2010-02-03 | 2017-01-31 | Signal Pharmaceuticals, Llc | Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors |
US9518032B2 (en) | 2010-04-30 | 2016-12-13 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of USP1 deubiquitinating enzyme activity |
US9139592B2 (en) | 2010-06-14 | 2015-09-22 | Trt Pharma Inc. | Modulators of Nrf2 and uses thereof |
EP2397482A1 (en) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
JP2012012332A (ja) | 2010-06-30 | 2012-01-19 | Dainippon Sumitomo Pharma Co Ltd | 新規アザインドール誘導体 |
US20130165426A1 (en) | 2010-07-06 | 2013-06-27 | Université de Montréal | Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators |
WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
TWI515187B (zh) | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
TWI527814B (zh) | 2010-12-16 | 2016-04-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類 |
TWI541241B (zh) | 2010-12-16 | 2016-07-11 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類 |
TWI501967B (zh) | 2010-12-16 | 2015-10-01 | Janssen R&D Ireland | 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類 |
JP5990106B2 (ja) | 2011-01-28 | 2016-09-07 | 佐藤製薬株式会社 | 縮環化合物 |
EP2694482A1 (en) | 2011-04-04 | 2014-02-12 | Siena Biotech S.p.A. | Wnt pathway antagonists |
WO2013025628A1 (en) | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Janus kinase inhibitor compounds and methods |
WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
EP3659599B1 (en) | 2011-10-19 | 2022-12-21 | Signal Pharmaceuticals, LLC | 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one for use in the treatment of glioblastoma multiforme |
US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
KR102064626B1 (ko) | 2012-02-24 | 2020-01-09 | 시그날 파마소티칼 엘엘씨 | Tor 키나제 억제자 복합 치료법을 사용한 비소세포 폐암의 치료 방법 |
EP2822944A1 (en) | 2012-03-05 | 2015-01-14 | Amgen, Inc. | Oxazolidinone compounds and derivatives thereof |
US9338896B2 (en) | 2012-07-25 | 2016-05-10 | Enthone, Inc. | Adhesion promotion in printed circuit boards |
WO2014043246A1 (en) | 2012-09-11 | 2014-03-20 | The Board Of Trustees Of The University Of Illinois | Enoyl reductase inhibitors with antibacterial activity |
AU2013202768B2 (en) * | 2012-10-18 | 2015-11-05 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
WO2014105952A2 (en) * | 2012-12-28 | 2014-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
JP6024979B2 (ja) | 2013-02-21 | 2016-11-16 | 学校法人金沢工業大学 | 難燃組成物、それを用いた難燃化処理方法および難燃材料 |
US20160008356A1 (en) | 2013-02-28 | 2016-01-14 | Signal Pharmaceuticals, Llc | Treatment of cancer with tor kinase inhibitors |
US9187454B2 (en) | 2013-03-13 | 2015-11-17 | Boston Biomedical, Inc. | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof |
TW201444820A (zh) | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶cdk9激酶抑制劑 |
EP3674300B1 (en) | 2013-06-21 | 2022-10-12 | Zenith Epigenetics Ltd. | Novel bicyclic bromodomain inhibitors |
BR112018010216B1 (pt) | 2015-11-20 | 2024-02-15 | Forma Therapeutics, Inc | Purinonas como inibidores da protease específica da ubiquitina 1 e composição farmacêutica compreendendo os referidos compostos |
-
2016
- 2016-11-18 BR BR112018010216-4A patent/BR112018010216B1/pt active IP Right Grant
- 2016-11-18 JP JP2018526219A patent/JP6964343B2/ja active Active
- 2016-11-18 AU AU2016356694A patent/AU2016356694B2/en active Active
- 2016-11-18 MX MX2018005925A patent/MX2018005925A/es unknown
- 2016-11-18 EP EP20168486.7A patent/EP3696181A1/en active Pending
- 2016-11-18 MX MX2021001186A patent/MX2021001186A/es unknown
- 2016-11-18 WO PCT/US2016/062837 patent/WO2017087837A1/en active Application Filing
- 2016-11-18 CN CN201680079504.4A patent/CN108473495B/zh active Active
- 2016-11-18 EP EP16805697.6A patent/EP3377493B1/en active Active
- 2016-11-18 US US15/355,887 patent/US10189841B2/en active Active
- 2016-11-18 KR KR1020187017482A patent/KR20180095539A/ko not_active Application Discontinuation
- 2016-11-18 RU RU2018121499A patent/RU2750151C2/ru active
- 2016-11-18 CN CN202210306502.1A patent/CN114702495A/zh active Pending
- 2016-11-18 IL IL300788A patent/IL300788A/en unknown
- 2016-11-18 SG SG11201804098TA patent/SG11201804098TA/en unknown
- 2016-11-18 CA CA3005353A patent/CA3005353A1/en active Pending
-
2018
- 2018-05-08 IL IL259220A patent/IL259220B/en active IP Right Grant
- 2018-08-01 US US16/051,879 patent/US10399980B2/en active Active
-
2019
- 2019-08-14 US US16/540,327 patent/US11161848B2/en active Active
-
2021
- 2021-04-06 IL IL282103A patent/IL282103B2/en unknown
- 2021-04-30 JP JP2021077708A patent/JP7273886B2/ja active Active
- 2021-09-30 US US17/490,482 patent/US20220281869A1/en active Pending
- 2021-10-27 AU AU2021257988A patent/AU2021257988B2/en active Active
-
2022
- 2022-11-08 JP JP2022178945A patent/JP2023011899A/ja active Pending
-
2023
- 2023-12-01 AU AU2023274204A patent/AU2023274204A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
MX2022005290A (es) | Compuestos heterociclicos como inmunomoduladores. | |
AU2018236800B2 (en) | DNA-PK inhibitors | |
PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
PH12018502710A1 (en) | Heterocyclic compounds as immunomodulators | |
AU2024202345A1 (en) | Nucleic acid carriers and therapeutic methods of use | |
PH12019501443A1 (en) | Benzooxazole derivatives as immunomodulators | |
MX2020002963A (es) | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 especifica de ubiquitina. | |
PH12016500024A1 (en) | Bromodomain inhibitor | |
NZ720478A (en) | Autotaxin inhibitor compounds | |
MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
MX2019015311A (es) | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. | |
MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
MX2015010125A (es) | Derivados de piridazinona-amidas. | |
PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
MX2019000536A (es) | Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1. | |
MX2019001011A (es) | Compuestos farmaceuticos. | |
MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
PH12015501038A1 (en) | Inhibitors of iap | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
MX2018005004A (es) | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. | |
WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES | |
PH12020500472A1 (en) | Autotaxin inhibitor compounds |